↓ Skip to main content

Comparative efficacy of fingolimod vs natalizumab A French multicenter observational study

Overview of attention for article published in Neurology, January 2016
Altmetric Badge

About this Attention Score

  • In the top 5% of all research outputs scored by Altmetric
  • High Attention Score compared to outputs of the same age (96th percentile)
  • High Attention Score compared to outputs of the same age and source (91st percentile)

Mentioned by

3 news outlets
3 blogs
10 tweeters


48 Dimensions

Readers on

41 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Comparative efficacy of fingolimod vs natalizumab A French multicenter observational study
Published in
Neurology, January 2016
DOI 10.1212/wnl.0000000000002395
Pubmed ID

Barbin, Laetitia, Rousseau, Chloe, Jousset, Natacha, Casey, Romain, Debouverie, Marc, Vukusic, Sandra, De Sèze, Jerome, Brassat, David, Wiertlewski, Sandrine, Brochet, Bruno, Pelletier, Jean, Vermersch, Patrick, Edan, Gilles, Lebrun-Frenay, Christine, Clavelou, Pierre, Thouvenot, Eric, Camdessanché, Jean-Philippe, Tourbah, Ayman, Stankoff, Bruno, Al Khedr, Abdullatif, Cabre, Philippe, Papeix, Caroline, Berger, Eric, Heinzlef, Olivier, Debroucker, Thomas, Moreau, Thibault, Gout, Olivier, Bourre, Bertrand, Créange, Alain, Labauge, Pierre, Magy, Laurent, Defer, Gilles, Foucher, Yohann, Laplaud, David A, , , Laetitia Barbin, Chloe Rousseau, Natacha Jousset, Romain Casey, Marc Debouverie, Sandra Vukusic, Jerome De Sèze, David Brassat, Sandrine Wiertlewski, Bruno Brochet, Jean Pelletier, Patrick Vermersch, Gilles Edan, Christine Lebrun-Frenay, Pierre Clavelou, Eric Thouvenot, Jean-Philippe Camdessanché, Ayman Tourbah, Bruno Stankoff, Abdullatif Al Khedr, Philippe Cabre, Caroline Papeix, Eric Berger, Olivier Heinzlef, Thomas Debroucker, Thibault Moreau, Olivier Gout, Bertrand Bourre, Alain Créange, Pierre Labauge, Laurent Magy, Gilles Defer, Yohann Foucher, David A. Laplaud, CFSEP and OFSEP groups, O. Anne, B. Audouin, E. Berger, D. Brassat, B. Brochet, B. Bourre, P. Cabre, J.P. Camdessanché, O. Casez, P. Clavelou, N. Collongues, M. Coustans, A. Créange, M. Debouverie, G. Defer, N. Derache, J. de Seze, D. Dive, A. Fromont, R. Guider, J. Grimaud, O. Heinzlef, A. Kiatkoswki, P. Labauge, D. Laplaud, C. Lebrun, E. Le Page, R. Marignier, T. Moreau, J.C. Ouallet, C. Papeix, J. Pelletier, S. Pittion, L. Rumbach, M. Schluep, P. Seeldrayers, I.S. Sennou, B. Stankoff, F. Thaite, A. Tourbah, E. Thouvenot, P. Vermersch, S. Vukusic, S. Wiertlewski, H. Zephir, Michel Clanet, Bertrand Fontaine, Jérôme de Seze, François Cotton, Vincent Dousset, David Laplaud, Romain Marignier, Françoise Durand-Dubief, Francis Guillemin, Sophie Pittion-Vouyovitch, Emmanuelle Leray, Emmanuelle le Page, Jean-Christophe Ouallet, Catherine Lubetzki, Alain Creange, Yann Mikaeloff, Kumaran Deiva, Marie Theaudin, Caroline Bensa, Nicolas Collongues, Hélène Zephir, Olivier Outteryck, Patrick Hautecoeur, Arnaud Kwiatkowski, Mikael Cohen, Agnès Fromont, Bertrand Audoin, Audrey Rico-Lamy, Nathalie Derache, Giovanni Castelnovo, William Camu, Jean-Philippe CAMDESSANCHE, Alexis Montcuquet, Abdelatif Al-Khedr, Olivier Casez, Anne-Marie Guennnoc, Jonathan Ciron, F. Durand-Dubief, M. Fleury, M. Clanet, L. Michel, A. Ruet, A. Rico, V. Deburghgraeve, M. Cohen, G. Castelnovo, C. Lubetzki, C. Bensa, J.M. Vallat, Chloé Rousseau


To compare natalizumab and fingolimod on both clinical and MRI outcomes in patients with relapsing-remitting multiple sclerosis (RRMS) from 27 multiple sclerosis centers participating in the French follow-up cohort Observatoire of Multiple Sclerosis. Patients with RRMS included in the study were aged from 18 to 65 years with an Expanded Disability Status Scale score of 0-5.5 and an available brain MRI performed within the year before treatment initiation. The data were collected for 326 patients treated with natalizumab and 303 with fingolimod. The statistical analysis was performed using 2 different methods: logistic regression and propensity scores (inverse probability treatment weighting). The confounder-adjusted proportion of patients with at least one relapse within the first and second year of treatment was lower in natalizumab-treated patients compared to the fingolimod group (21.1% vs 30.4% at first year, p = 0.0092; and 30.9% vs 41.7% at second year, p = 0.0059) and supported the trend observed in nonadjusted analysis (21.2% vs 27.1% at 1 year, p = 0.0775). Such statistically significant associations were also observed for gadolinium (Gd)-enhancing lesions and new T2 lesions at both 1 year (Gd-enhancing lesions: 9.3% vs 29.8%, p < 0.0001; new T2 lesions: 10.6% vs 29.6%, p < 0.0001) and 2 years (Gd-enhancing lesions: 9.1% vs 22.1%, p = 0.0025; new T2 lesions: 16.9% vs 34.1%, p = 0.0010) post treatment initiation. Taken together, these results suggest the superiority of natalizumab over fingolimod to prevent relapses and new T2 and Gd-enhancing lesions at 1 and 2 years. This study provides Class IV evidence that for patients with RRMS, natalizumab decreases the proportion of patients with at least one relapse within the first year of treatment compared to fingolimod.

Twitter Demographics

The data shown below were collected from the profiles of 10 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 41 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Brazil 1 2%
Unknown 40 98%

Demographic breakdown

Readers by professional status Count As %
Other 9 22%
Student > Ph. D. Student 6 15%
Student > Bachelor 3 7%
Professor > Associate Professor 3 7%
Researcher 3 7%
Other 8 20%
Unknown 9 22%
Readers by discipline Count As %
Medicine and Dentistry 12 29%
Neuroscience 6 15%
Pharmacology, Toxicology and Pharmaceutical Science 4 10%
Unspecified 2 5%
Biochemistry, Genetics and Molecular Biology 1 2%
Other 5 12%
Unknown 11 27%

Attention Score in Context

This research output has an Altmetric Attention Score of 49. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 07 June 2017.
All research outputs
of 17,413,731 outputs
Outputs from Neurology
of 16,907 outputs
Outputs of similar age
of 349,614 outputs
Outputs of similar age from Neurology
of 260 outputs
Altmetric has tracked 17,413,731 research outputs across all sources so far. Compared to these this one has done particularly well and is in the 96th percentile: it's in the top 5% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 16,907 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 16.9. This one has done particularly well, scoring higher than 94% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 349,614 tracked outputs that were published within six weeks on either side of this one in any source. This one has done particularly well, scoring higher than 96% of its contemporaries.
We're also able to compare this research output to 260 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.